Author
By Patrick O’Leary I’ve been thinking a lot lately about how our society regulates the integrity of scientific research in an era of fierce competition for diminishing grants and ultracompetitive academic appointments. When I shared…
By Patrick O’Leary The cover story of the March 4, 2013 issue of Time Magazine is a piece by Steven Brill titled Bitter Pill: Why Medical Bills Are Killing Us. The article has apparently made…
By Patrick O’Leary When I read Susannah Meadows’s article in last week’s New York Times Magazine, The Boy with a Thorn in His Joints, I was at a bit of a loss how to respond. The…
By Patrick O’Leary While reading some of the great articles from the health section of the New York Times over the holidays it struck me that such articles, in their need to be concise and…
By Patrick O’Leary As I’ve written about previously on this blog, the consequences for the FDA of budget sequestration under the Budget Control Act of 2011 could be fairly severe (as well as raise some…
By Patrick O’Leary In the October 22 edition of The New Yorker, Michael Specter wrote a fascinating article about the growing and exciting science of the human microbiome, the ecosystem of ten thousand or so…
By Patrick O’Leary A friend and I were having a conversation about health policy the other day when he observed that drug regulators like FDA face an impossible task in terms of public expectations: as…
By Patrick O’Leary Looking back over last month’s health-related news, two articles published on The Atlantic’s website stand out to illustrate a tension that has received a great deal of focus in Medicare reform circles,…
By Patrick O’Leary Back in February, President Obama’s FY 2013 budget authorized $4.5 billion for the Food and Drug Administration (FDA), about $2 billion of which was to come from user fees, the fees paid…
